Methods of treatment with glycosylated antibodies

Abstract

The present invention relates to methods of treating a human patient suffering from rheumatoid arthritis, comprising: obtaining a CHO cell comprising antibody heavy and light chain genes which are constituted of cDNA and in a form that enables balanced expression of the light and heavy chains of a human or humanized recombinant antibody; culturing the CHO cell in a serum-free media; purifying the resulting recombinant antibody; and administering a therapeutically effective amount of the antibody expressed and glycosylated in a CHO cell expression system to said human patient.

1 - 48 . (canceled) 
     
     
         49 . A method of treating a human patient suffering from rheumatoid arthritis, comprising:
 a) obtaining a CHO cell comprising antibody heavy and light chain genes which are constituted of cDNA and in a form that enables balanced expression of the light and heavy chains of a human or humanized recombinant antibody;   b) culturing the CHO cell in a serum-free media;   c) purifying the resulting recombinant antibody; and   d) administering a therapeutically effective amount of the antibody expressed and glycosylated in a CHO cell expression system to said human patient.   
     
     
         50 . The method of  claim 49  wherein the cell is cultured in said serum-free medium for greater than two months. 
     
     
         51 . The method of  claim 49  wherein the cell is cultured in said serum free medium for greater than five months. 
     
     
         52 . The method of  claim 49  wherein the culture undergoes multiple passage. 
     
     
         53 . The method of  claim 49  wherein the serum free medium further comprises water, an osmolarity regulator, a buffer, an energy source, L-glutamine and at least one additional amino acid, an inorganic iron source and a recombinant growth factor wherein each component of said medium is obtained from a source other than directly from an animal source. 
     
     
         54 . The method of  claim 53  wherein the medium is devoid of bovine serum albumin, pure human transferrin and soybean lecithin. 
     
     
         55 . The method of  claim 53  wherein the growth factor is recombinant insulin. 
     
     
         56 . The method of  claim 49 , wherein the recombinant antibody is able to activate complement. 
     
     
         57 . The method of  claim 49  wherein the recombinant antibody is a monoclonal antibody. 
     
     
         58 . The method of  claim 49  wherein the recombinant antibody is a humanized antibody. 
     
     
         59 . The method of  claim 49  wherein the recombinant antibody is a human antibody.